Subsequently, loss of functional p53-signaling in colorectal cancer, a typical late-stage event in the disease, may fail to suppress DPYD expression and add another level of complexity to 5-FU treatment by contributing to drug resistance. Here, TP53 is linked to colorectal cancer.